Support and Resistance Levels
Past performance
About Corona Remedies Ltd Corona Remedies Limited, incorporated on August 27, 2004, is an Indian pharmaceutical company headquartered in Gujarat. Initially established as a private limited company, it transitioned to a public limited entity in 2024. The company operates two manufacturing facilities, located in Solan, Himachal Pradesh, and Bhayla, Ahmedabad in Gujarat, which support its production activities.
The firm specializes in manufacturing, trading, and marketing pharmaceutical products across multiple therapeutic areas, including women's healthcare, cardiovascular diseases, diabetes management, pain relief, and urology. Corona Remedies has progressively expanded its product portfolio, launching various specialized divisions such as Gynaecology (2008), Cardiology (2013), Cardiovascular Disease and Solis (2016), and Urology (2023). Its latest divisions, Radiance and Solaris, were introduced in 2022.
The company commissioned its first manufacturing plant in Solan in 2007 and expanded further with production facilities in Ahmedabad in 2021 to scale operations. With a strong focus on addressing diverse healthcare challenges, Corona Remedies has positioned itself in high-demand therapeutic segments, aiding its market reach and growth prospects.
Currently, the company is planning an Initial Public Offering (IPO) to raise ₹800 crore through an offer for sale of equity shares priced at ₹10 each, aimed at furthering its financial objectives and enhancing its market presence.